Houston, TX, United States of America

Clifford Dacso

This inventor holds 4 USPTO granted patents and 4 published patent applications. Top assignee: Baylor College of Medicine. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clifford Dacso. Retrieved from https://idiyas.com/inventor/clifford-dacso

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 75.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2022-2026

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Clifford Dacso

Introduction

Clifford Dacso is a notable inventor based in Houston, Texas, recognized for his significant contributions to cancer treatment through innovative methodologies. With a total of three patents to his name, Dacso's work focuses on the targeting of SRC-3 in immune cells, particularly T regulatory cells, to enhance therapeutic outcomes in cancer patients.

Latest Patents

Dacso's latest patent involves the targeting of SRC-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer. This patent outlines methods and compositions that leverage the targeting of SRC-3 in T regulatory cells, which has shown effectiveness in eradicating tumors in mammals. The patent also discusses the use of CRISPR technology to modify T regulatory cells ex vivo, creating cells suitable for adoptive cell transfer. Additionally, it mentions the administration of agents that target SRC-3 to enhance treatment efficacy.

Career Highlights

Clifford Dacso is affiliated with the Baylor College of Medicine, where he conducts research and develops innovative cancer therapies. His work is characterized by a commitment to advancing medical science and improving patient outcomes through targeted immunotherapy.

Collaborations

Dacso collaborates with esteemed colleagues, including Bert W O'Malley and Sang Jun Han, to further his research and explore new avenues in cancer treatment.

Conclusion

Clifford Dacso's innovative work in targeting SRC-3 in immune cells represents a significant advancement in cancer therapy. His contributions continue to pave the way for new treatment methodologies that hold promise for improving patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…